Hydrochloric Acid → Erlotinib hydrochloride

HRID 243531

반응식

HRID 243531 반응식
[CH3:1][O:2][CH2:3][CH2:4][O:5][C:6]1[CH:11]=[C:10]2[C:12]([NH:16][C:17]3[CH:22]=[C:21]([C:23]#[CH:24])[CH:20]=[CH:19][CH:18]=3)=[N:13][CH:14]=[N:15][C:9]2=[CH:8][C:7]=1[O:25][CH2:26][CH2:27][O:28][CH3:29].C(OCC)=O.[ClH:35]>C(O)(C)C>[CH3:1][O:2][CH2:3][CH2:4][O:5][C:6]1[CH:11]=[C:10]2[C:12]([NH:16][C:17]3[CH:18]=[CH:19][CH:20]=[C:21]([C:23]#[CH:24])[CH:22]=3)=[N:13][CH:14]=[N:15][C:9]2=[CH:8][C:7]=1[O:25][CH2:26][CH2:27][O:28][CH3:29].[ClH:35]

참가 물질

5

반응물 3

HCID 313Hydrochloric AcidHCID 8025Ethyl formateHCID 176870Erlotinib

생성물 1

HCID 176871Erlotinib hydrochloride수율 93.6%

시약·촉매·용매 1

HCID 3776Isopropanol용매

반응 조건

온도
5 °C

실험 절차

10.0 g crystal form IV of erlotinib base was added to 200 ml ethyl formate, heated to 0-10° C., 6.4 g isopropanol saturated with HCl gas was added dropwise, after dripping, stirred for 30 minutes while maintaining the temperature, stirred for 1 hour at 0-15° C. before filtration, dried at 50° C. to obtain 10.2 g sample of crystal form A. The yield was 93.6% and the purity was 99.7% (by HPLC).

후처리

  1. temperaturewhile maintaining the temperature
  2. stirringstirred for 1 hour at 0-15° C. before filtration
  3. customdried at 50° C.
  4. customto obtain 10.2 g sample of crystal form A

출처 및 근거

ORD 기록
ord-aecce3c5959c49b5b418011801015501
출처 데이터셋
uspto-grants-2014_02
특허 번호
US08653264B2

연결된 노트

불러오는 중…